Trump Administration to Announce Findings on Autism and Tylenol Use During Pregnancy

The Trump administration is expected to announce findings linking the use of Tylenol (acetaminophen) during pregnancy to an increased risk of autism in children. This announcement is anticipated during a White House event on Monday, with Health and Human Services Secretary Robert F. Kennedy Jr. expected to participate.

President Donald Trump previewed the announcement at a memorial service on Sunday, stating, "I think we found an answer to autism."

The proposed link between prenatal acetaminophen use and autism has been a subject of scientific debate. Some studies have suggested a potential association, but findings have been inconsistent, and no causal relationship has been established.

Kenvue, the manufacturer of Tylenol, has defended the safety of its product. In a statement, the company asserted that independent scientific evidence does not support a causal link between acetaminophen use during pregnancy and autism. They expressed concern that suggesting otherwise could pose health risks to expecting mothers.

Medical experts emphasize that acetaminophen is widely regarded as a safe option for managing pain and fever during pregnancy. They caution that untreated maternal fever can itself pose risks to fetal development.

Autism diagnoses in the United States have risen significantly over the past two decades. According to the Centers for Disease Control and Prevention, the prevalence among 8-year-olds increased from 0.66% in 2000 to 2.77% in 2020. Researchers attribute this rise to a combination of factors, including increased awareness, broader diagnostic criteria, and potential environmental influences.

The forthcoming announcement is expected to reignite discussions on the causes of autism and the safety of common medications during pregnancy.